Warning Letter — Eurofins SF Analytical Laboratories, Inc.
The FDA issued a Warning Letter to Eurofins SF Analytical Laboratories, Inc. following an inspection by the Center for Drug Evaluation and Research (CDER). The letter details specific deviations from Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.
This affects Eurofins SF Analytical Laboratories, Inc., as well as pharmaceutical manufacturers who contract this facility for analytical testing services. It primarily impacts laboratory management and quality oversight functions.
The issuance of a Warning Letter to a major contract testing laboratory suggests potential systemic weaknesses in laboratory controls or data integrity. For pharmaceutical companies relying on third-party analytical results for batch release or stability testing, this enforcement action may necessitate a formal risk assessment of the data provided by the laboratory and a re-evaluation of their vendor qualification status.
Quality units at drug manufacturing firms should review the compliance status of contract labs and verify that analytical methods and data management systems align with CGMP expectations. Any firm utilizing this facility for drug testing should evaluate the potential impact on released or pending batches.
FDA Warning Letter issued to: Eurofins SF Analytical Laboratories, Inc.. 10/06/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026
Open in openFDA / FDA.gov